Jetpharma SA’s Post

Do come by and I'll inform you about the latest and greatest developments that will add value to your #medical #mould business. See you at #CPHI2024 #Milan IGS GeboJagema

In Milan for what is also my third CPHI (where does the time go??), and honestly it just gets better every year - as does our blog of course! ✏️ Read along with Vivian X. and I as we take to the floor, attending conference sessions and panels, with more content than ever before I just wish we could be in five places at once. We talk the future of manufacturing, innovations in packaging, sustainability, and diversity in pharma. Also on which stands have the best coffee - everything you need to know! 🌳 ♻️ 💊 🔬 Read the blog here: https://lnkd.in/eUbbYaG5 #CPHIMilan #manufacturinginpharma #sustainability #blog

🗞 Today's Daily #MedTech roundup brings news of funding, regulatory approvals, and more! Explore below 👇 1️⃣ Diagnostics startup Noze awarded $1.8m grant for World Tuberculosis Day 👃 The grant will go towards the trial examining the company’s handheld breathalyser designed to detect and screen for various medical conditions, including infectious diseases such as tuberculosis. 📣 Karim A., CEO, wrote: “The ability to perform high-yield, low-cost screening of tuberculosis is a critical driver in ending the global epidemic.” 🔗 https://lnkd.in/d3F-Ud72 ====================== 2️⃣ RefleXion Medical to incorporate Limbus AI software into radiotherapy planning system 👁 The integration of Limbus AI’s Limbus Contour software into RefleXion X1 radiotherapy treatment planning system is aimed at expediting the process of cancer treatment planning. 📣 RefleXion co-founder and CTO Samuel Mazin said: “We have found Limbus Contour’s AI-driven solution to be a technology leader in speed, accuracy and versatility.” 📣 Limbus AI CEO Karl Otto commented: “X1 images demonstrate high resolution, exceptional contrast, and minimal noise and motion artifacts. 🔗 https://lnkd.in/djdfbjQU ====================== 3️⃣ Baird Medical receives Class III certificate for thyroid treatment needle 💉 The certificate recognises the needle’s advanced design for treating thyroid nodules, utilising rare earth ceramic materials for improved heat resistance, chemical stability, and electrical insulation. 📣 Founder and CEO Haimei Wu said: “The introduction of the Ceramic Thyroid Ablation Needle signifies another breakthrough innovation in the field of microwave ablation and is a testament to our ongoing commitment to innovation and research." 🔗 https://lnkd.in/dRZZT6-f ====================== 📰 Follow Guided Solutions to receive the latest #MedTech news daily and subscribe to our weekly newsletter: https://lnkd.in/dJRDenY #MedicalDevice #MedicalEquipment #Medicine #Surgeons #Funding #Innovation #GuidedSolutions

We are excited to share our latest research at the upcoming Health Technology Assessment international (HTAi) 2024 event in Seville! Be sure to mark your calendars and book a #braindate with the presenters. 1. A European Value Assessment Framework For Next Generation Sequencing And Comprehensive Genomic Profiling Oncology Diagnostics - Oral Presentation 🗓 Date & Time: Tuesday, 18 June 2024, 14:35 – 15:35 📍 Location: Room – Andalucia 5, Barceló Convention Centre Description: In a joint collaboration between the MTRG and IECS - Instituto de Efectividad Clínica y Sanitaria, led by Dr Panos Kanavos and Dr Prof. Federico Augustovski, MD, MSc, PhD, we developed a value assessment framework to provide transparent and explicit criteria for the evaluation and coverage of NGS/CGP diagnostics in European oncology settings. Presenter: Madeleine Haig 2. Incentives To Incorporate Innovation Into Care Delivery Processes: A Scoping Review And SWOT Analysis - Poster Presentation 📍 Location: Poster Exhibition Area, Atrio 3 Description: Part of HI-PRIX HORIZON, this research investigates the strengths, weaknesses, opportunities, and threats of financial and non-financial incentive mechanisms that aim to improve access to innovative medical technologies. Presenter: Madeleine Haig 3. Do Patient Contributions Matter? A Thematic Document Analysis of NICE Ultra-Rare Disease Appraisals - Poster Presentation 📍 Location: Poster Exhibition Area, Atrio 3 Description: This study analyses inputs from patient organisations and patient experts in technology appraisals for ultra-rare diseases in the UK and seeks to understand how they are taken into account in NICE final recommendations. Presenter: Arianna Gentilini See you there! #HTAi2024 #healthtechnologyassessment #pharmaceuticalpolicy #NICE #patientorganisations #valueassessment

Last week, we introduced you to our four presenting portfolio companies at this year's Innovation Showcase. In celebration of Start Codon's five-year anniversary, this year our presenting companies will also be joined by Adora Digital Health, Verinnogen, Cardiac-Tech Ltd, and Proxximos, who will be giving live demonstrations of their technology, giving you the chance to see their progress in action and meet with members of their team to find out more.   Kicking off our series of exhibiting companies, meet Verinnogen!   Verinnogen has developed a novel, contact-based surface profiling tool that will transform the way we interact with, understand, and measure physical objects such as subcutaneous tumours and other biological tissues.   Designed to address the problem of error-prone calliper measurements in pre-clinical cancer research, Verinnogen's moveable pin approach has already demonstrated a four-fold reduction in operator variability in vivo, a key drawback of calliper-based measurements, using their prototype device.   The 3D profiling technology has also been developed to integrate additional measurements, such as body condition scoring, surface temperature, and tissue elasticity.   To find out more about Verinnogen's innovative technology and speak with Dr Isaac Johnson, CEO, and Dr Mike Irvine, CTO at Verinnogen, register your interest here: https://rb.gy/qc7bfg   Stay tuned this week to learn more about the rest of our exhibiting companies!   #3Dprofiling #CancerResearch #MedicalDevice

#WhatsUpSIgN We are proud to announce that SIgN was featured at last week’s A*STAR - Agency for Science, Technology and Research BioMedical Research Council (BMRC) Townhall! These awards highlight the scientific excellence and impact of our SIgN-tists’ work across all areas of A*STAR’s mission to Create Growth and Improve Lives. BMRC Collaborative Paper Awards (3 out of 3 awards!): 1.      Deterministic reprogramming of neutrophils within tumors (top left) 2.      Single-Cell Atlas of Lineage States, Tumor Microenvironment, and Subtype-Specific Expression Programs in Gastric Cancer (bottom right) 3.      Spatially informed clustering, integration, and deconvolution of spatial transcriptomics with GraphST (top right) BMRC IAF-PP Industry Value Capture Award: 1.      SinGapore ImmuNogrAm for Immuno-OncoLogy (SIGNAL) (bottom left) BMRC Star Mentor Awards: 1.      Wu Wei Congratulations again to all our SIgN-tists and our fellow BMRC colleagues on the fruits of their hard work! For the full list of SIgN awardees and links to the published manuscripts, please see the first comment below. #immunology #SIgNCentreforExcellence #CreatingGrowth #EnhancingLives #ASTARsg Graphics attribution: https://lnkd.in/gfrd3H_u

As we anticipate #EHA2024, we’re looking back at our achievements at EHA 2023 in Frankfurt. Our live, hybrid symposium on CAR T-cell therapy not only attracted HCPs but significantly increased their knowledge, with 89% ready to apply learnings clinically. As we gear up for #EHA2024, join us in revisiting last year's highlights and learnings: https://loom.ly/Xh3jmrk #Hematology #MedicalEducation

This week, we held our 4th Consortium meeting for ASCERTAIN at the European Hematology Association (EHA) Congress in Madrid. During this meeting, we presented our results after 1.5 years of the project to our international advisory board and discussed the next steps. Our primary findings are based on input from stakeholders and the results of our scoping reviews. These reviews concentrated on key topics within the ASCERTAIN work package, including pricing, (cost-) effectiveness models, and reimbursement. Additionally, we examined broader policy considerations affecting patient access to health technologies. This includes European Union market conditions, the role of innovation partnerships in developing new health technologies, methods for incorporating patient and citizen values into market entry and reimbursement decisions, and approaches for including environmental outcomes in health technology assessments (#HTA). During the meeting, we delved, together with the advisory board, deeper into what constitutes fair pricing and explored the potential usefulness of expert elicitation in the context of single-arm trials. The discussions were highly stimulating and will help us advance our project and achieve our goals. With our policy decision tool, we aim to enhance transparency, reduce uncertainty, stimulate innovation in high-need areas, expedite patient access, and facilitate sustainable planning. We are focusing on precision cancer medicine, #CAR-T cell therapies, and next-genome sequencing for testing these tools. Later in the project, the user-friendly tools will be hosted on a cloud-based platform, adhering to open science principles. A big thank you to all partners and the representatives of our stakeholders for joining us on this journey. #EHA2024 #highprices #hematology #oncology #affordability #accessibility #teamwork Marcel Langone Nicolas Xander Tom Belleman Maureen Rutten-van Mölken Frederick Thielen Tomas Tesar Mirjana Huic Maximilian Salcher-Konrad Eline Aas Pia Henkel Yansi Wu Anne Hendrickx Andrew Pomasanski Pr. Isabelle Durand-Zaleski Robin Doeswijk Gauthier Quinonez Katie Joyner Monica Racovita Maria Grassetto Ermanno Pallaoro Oliver Groene, PhD Lena Jessen

🌟 Reflecting on a week of innovation and connection at the NZ Life Sciences Summit 2024 🌟 Deb Cooper GAICD CPPP, Joseph (Joe) Badolato and Madeleine Clarke from Adjutor Healthcare Group attended the Life Sciences Summit 2024, held at the Takina Wellington Convention and Exhibition Centre in Wellington, New Zealand, from March 11 to March 12, 2024. Here are some insights from the conference: 🔬 On average, 66 New Zealanders are diagnosed with cancer every day, highlighting the pressing need for advancements in healthcare. 🤖 The potential of AI to significantly accelerate development of antiaging medicine is within reach. 📊 Discussions around R&D tax credits shed light on opportunities for streamlining processes and leveraging resources more effectively. 💡 New Zealand's robust healthcare system and willingness of up to 10% of the population to participate in clinical trials position the country as an attractive destination for medical research, with room for further growth through strategic enhancements. 💰 Exciting news of NZD70M funding for the RNA Platform over 7 years underscores the country's commitment to innovation and pandemic preparedness. 🌍 Lively discussions centered on positioning technologies like mRNA to ensure New Zealand remains at the forefront of biotechnological advancements. Prior to the conference, our team had the pleasure of attending the Touchdown Event, setting the stage for a week filled with insights and connections. This event was not just about networking - it provided valuable insights into the local ecosystem and opportunities to forge connections with high-growth companies and research organisations. It was truly inspiring to immerse ourselves in Wellington's unique spirit of innovation. Following the conference, our journey continued with the Innovation and Discovery Tour, exploring the Gracefield Innovation Quarter and the Malaghan Institute. This tour deepened our understanding of the ground-breaking research being conducted in immunology and immunotherapy (including with CAR T therapy). It was an action-packed week filled with insights, connections, and a broader understanding of the contributions New Zealand brings to the biotechnology table. Looking forward to continuing this journey of innovation and collaboration! #LifeSciences #Innovation #Biotechnology #Healthcare #NewZealand #ResearchCommunity #Collaboration #AdjutorAdvantage